What is the clinical treatment effect of Erdafitinib/Bocco?

Erdafitinib (Erdafitinib) is a new type of oral small molecule targeted drug, and its clinical application represents the latest progress in tumor treatment. Its target is the FGFR (fibroblast growth factor receptor) pathway, which is abnormally activated in some cancers, thereby promoting the unlimited proliferation and metastasis of tumor cells. In the disease of bladder cancer, FGFR2 or FGFR3 gene mutations and fusions are relatively common. Such patients are often insufficiently sensitive to traditional chemotherapy. Erdafitinib was developed to solve this problem.

Judging from overseas clinical application experience, erdafitinib has been approved by the FDA for the treatment of patients with locally advanced or metastatic bladder cancer, especially those with FGFR gene mutations. After failure of standard platinum-containing chemotherapy, patients using erdafitinib can often achieve disease control, and some cases even experience tumor shrinkage. Such effects provide new treatment options for patients for whom traditional treatments are limited. Compared with chemotherapy, the advantage of erdafitinib lies in its precision and targeting. It only exerts its effect on patients with specific molecular markers and does not affect all cells indiscriminately. Therefore, the overall tolerability is better and the patient's quality of life can be relatively improved.

It should be noted that erdafitinib is not effective in all patients with bladder cancer. It can only be used if the patient is confirmed to have an FGFR2 or FGFR3 mutation through genetic testing. This reflects the core concept of "precision medicine", which is to determine treatment paths through molecular typing. In addition, patients may also experience side effects during medication, such as oral mucositis, dry skin, nail abnormalities, etc. These adverse reactions are controllable in most cases, but doctors require regular monitoring and timely dosage adjustment.

Overall, the effectiveness of erdafitinib in clinical treatment has been internationally recognized. It has not only changed the treatment pattern of some bladder cancer patients, but also prolonged survival time to a certain extent.

Reference materials：https://www.balversa.com/